Apraglutide, a novel glucagon‐like peptide‐2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo‐controlled, randomi...

por Eliasson, Johanna, Hvistendahl, Mark K., Freund, Nanna, Bolognani, Federico, Meyer, Christian, Jeppesen, Palle B.
Publicado 2021

Apraglutide, a novel once‐weekly glucagon‐like peptide‐2 analog, improves intestinal fluid and energy absorption in patients with short bowel syndrome: An open‐label phase 1 and 2...

por Eliasson, Johanna, Hvistendahl, Mark K., Freund, Nanna, Bolognani, Federico, Meyer, Christian, Jeppesen, Palle B.
Publicado 2022

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study

por Naimi, Rahim Mohammad, Hvistendahl, Mark Krogh, Thomassen, Lise Margrete, Johnsen, Hanna, Christiansen, Charlotte Bayer, Holst, Jens Juul, Hartmann, Bolette, Jeppesen, Palle Bekker
Publicado 2021

Effects of glepaglutide, a long‐acting glucagon‐like peptide‐2 analog, on intestinal morphology and perfusion in patients with short bowel syndrome: Findings from a randomized phas...

por Naimi, Rahim M., Hvistendahl, Mark K., Poulsen, Steen S., Kissow, Hannelouise, Pedersen, Jens, Nerup, Nikolaj A., Ambrus, Rikard, Achiam, Michael P., Svendsen, Lars B., Jeppesen, Palle B.
Publicado 2022

Effects of glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, on markers of liver status in patients with short bowel syndrome: findings from a randomised phase 2...

por Naimi, Rahim Mohammad, Hvistendahl, Mark, Nerup, Nikolaj, Ambrus, Rikard, Achiam, Michael Patrick, Svendsen, Lars Bo, Grønbæk, Henning, Møller, Holger Jon, Vilstrup, Hendrik, Steensberg, Adam, Jeppesen, Palle Bekker
Publicado 2019